Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
On July 27, 2023, the Eli Lilly drug company announced the results of two clinical trials: Participants in SURMOUNT-3, after 12 weeks of intensive lifestyle intervention, achieved an additional 21.1% mean weight loss with tirzepatide for a total mean weight loss of 26.6% from study entry over 84 weeks Participants in SURMOUNT-4 achieved 21.1% weight loss during a 36-week tirzepatide lead-in period and an additional 6.7% weight loss during a 52-week continued treatment period, for a total mean weight loss of 26.0% over 88 weeks Thats impressive
There are no generic versions of Qsymia and Wegovy, which can make them more expensive than generic alternatives
On average, participants lost 15.1% of their body weight after 68 weeks compared to 2.4% of body weight from those on the placebo
This medication is particularly useful for people whose weight management challenges are primarily driven by cravings, emotional eating, or food addiction rather than hunger
.webp)
US$ 29.03
US$ 22.23
:max_bytes(150000):strip_icc()/PurposeofSubcutaneousFatandHowtoLosetheExtra-final-a3b5cabbcbb04caa8c11d2dd1c58a7d5.png)
US$ 23.19
US$ 22.99
US$ 22.55
US$ 27.50
